A COMPARISON OF PHENOXYPROPAZINE AND AMYTRYPTILINE IN DEPRESSION
Abstract
Phenoxypropazine is compared with amitryptiline in the treatment of 78 hospitalised patients suffering from primary depressive disorders. Most patients on either drug responded well, there being no significant difference in outcome between the 2 drug groups. Endogenous and reactive depressions showed no difference in response to phenoxypropazine. Side effects were few and did not interfere with treatment. It is considered that phenoxypropazine is a useful antidepressant of equal effectiveness to amitryptiline.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
